See more : Korea Electric Power Corporation (KEP) Income Statement Analysis – Financial Results
Complete financial analysis of Mind Medicine (MindMed) Inc. (MMED.NE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mind Medicine (MindMed) Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ecolomondo Corporation (ECLMF) Income Statement Analysis – Financial Results
- Sejal Glass Limited (SEJALLTD.NS) Income Statement Analysis – Financial Results
- Metallurgical Corporation of China Ltd. (1618.HK) Income Statement Analysis – Financial Results
- Bright Green Corporation (BGXX) Income Statement Analysis – Financial Results
- Leen Alkhair Trading Company (9555.SR) Income Statement Analysis – Financial Results
Mind Medicine (MindMed) Inc. (MMED.NE)
About Mind Medicine (MindMed) Inc.
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 52.12M | 36.17M | 34.79M | 18.63M | 12.94M |
| General & Administrative | 41.74M | 30.16M | 59.07M | 14.40M | 5.45M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 41.74M | 30.16M | 59.07M | 14.40M | 5.45M |
| Other Expenses | 0.00 | 2.00K | 106.00K | 0.00 | 0.00 |
| Operating Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 18.36M |
| Cost & Expenses | 93.87M | 66.33M | 93.85M | 33.03M | 18.36M |
| Interest Income | 4.66K | 0.00 | 0.00 | 0.00 | 17.14 |
| Interest Expense | 0.00 | 0.00 | 359.00K | 164.00K | 0.00 |
| Depreciation & Amortization | 3.16M | 3.18M | 2.62M | 206.30K | 171.86K |
| EBITDA | -90.70M | -66.32M | -91.15M | -33.03M | 48.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -93.87M | -66.33M | -96.36M | -33.03M | -18.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.87M | 9.54M | -339.00K | -907.00K | 48.00K |
| Income Before Tax | -95.73M | -56.80M | -94.19M | -33.94M | -18.34M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -12.71M | -1.16M | 163.45K | 48.15 |
| Net Income | -95.73M | -56.80M | -93.04M | -33.94M | -18.34M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.44 | -1.84 | -3.40 | -1.91 | -2.68 |
| EPS Diluted | -2.44 | -1.84 | -3.40 | -1.91 | -2.68 |
| Weighted Avg Shares Out | 39.16M | 30.86M | 27.38M | 17.75M | 6.85M |
| Weighted Avg Shares Out (Dil) | 39.16M | 30.86M | 27.38M | 17.75M | 6.85M |
Source: https://incomestatements.info
Category: Stock Reports